SCHEMBL2632465

SCHEMBL2632465

CCC(C)Cc1cccc(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.67
TSHR P16473 1/20 0.47
RECQL P46063 1/20 0.47
TAAR1 Q96RJ0 3/20 0.46
CHRM2 P08172 1/20 0.44
CYP3A4 P08684 2/20 0.44
IDO1 P14902 2/20 0.44
AGXT P21549 2/20 0.44
HTR3E A5X5Y0 3/20 0.43
HTR3B O95264 3/20 0.43
HTR3A P46098 3/20 0.43
HTR3D Q70Z44 3/20 0.43
HTR3C Q8WXA8 3/20 0.43
AOC3 Q16853 1/20 0.43
SIGMAR1 Q99720 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
PYCR1 P32322 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21779350 1.00 PNMT (0.67) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL25509152 0.85 PNMT (0.62) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL15314120 0.85 PNMT (0.62) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL28951517 0.83 PNMT (0.65) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL777207 0.82 PNMT (0.74) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL8293508 0.81 PNMT (0.53) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL6679797 0.81 PNMT (0.61) PNMTTSHRRECQLTAAR1CHRM2
SCHEMBL14478283 0.80 PNMT (1.00) PNMTTSHRRECQLTAAR1CYP3A4
SCHEMBL30363681 0.80 PNMT (1.00) PNMTTSHRRECQLTAAR1CYP3A4
SCHEMBL266685 0.80 PNMT (1.00) PNMTTSHRRECQLTAAR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10577368-B2 A3 adenosine receptor agonists THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-03-03 US disclosed
US-20200030287-A1 PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS RESEARCH TRIANGLE INSTITUTE 2020-01-30 US disclosed
EP-2770987-B1 NOVEL COMPOUNDS THAT ARE ERK INHIBITORS MERCK SHARP & DOHME (US) 2018-04-04 EP disclosed
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
US-20120101032-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2012-04-26 US disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101032-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, EIF4A2 PNMT 3361/4885TSHR 4217/4885RECQL 237/4885
US-20200030287-A1 PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS NPFFR1, NPFFR2, NPBWR1 PNMT 867/4885TSHR 126/4885RECQL 4827/4885
US-10577368-B2 A3 adenosine receptor agonists ADORA3, ADORA2B, ADORA1 PNMT 1777/4885TSHR 289/4885RECQL 114/4885
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACSL3, SLCO4C1, SLC38A7 PNMT 4743/4885TSHR 2633/4885RECQL 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.